These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.
    Author: Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM.
    Journal: J Natl Cancer Inst; 1988 Mar 02; 80(1):60-3. PubMed ID: 3257526.
    Abstract:
    A phase I trial of repetitive weekly cycles of human recombinant interleukin-2 (IL-2) was performed in 23 patients with metastatic carcinoma. Patients received 4 days of IL-2 each week, followed by 3 days of observation, for 4 consecutive weeks. IL-2 was administered iv at 1.0 or 3.0 X 10(6) U/m2/day by one of three schedules involving continuous or bolus infusions. All treatment was carried out in a general hospital ward without intensive care unit monitoring or support. Seventeen patients had metastatic renal cell carcinoma; three of these demonstrated measurable (greater than 50% shrinkage) partial responses. This study demonstrates that IL-2 given alone without lymphokine-activated killer cells in this manner can induce antitumor effects with acceptable toxicity.
    [Abstract] [Full Text] [Related] [New Search]